These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18707637)

  • 1. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
    Mairs RJ; Boyd M
    Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors.
    Mairs RJ; Boyd M
    Semin Nucl Med; 2011 Sep; 41(5):334-44. PubMed ID: 21803183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
    Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
    J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
    Boyd M; Sorensen A; McCluskey AG; Mairs RJ
    J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
    McCluskey AG; Boyd M; Gaze MN; Mairs RJ
    Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
    Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
    J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
    Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
    Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
    Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
    Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
    Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
    Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
    Grünwald F; Ezziddin S
    Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine.
    Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kurihara H; Kawamoto H;
    Ann Nucl Med; 2015 Jul; 29(6):543-52. PubMed ID: 25773397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
    Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
    Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
    Nguyen C; Faraggi M; Giraudet AL; de Labriolle-Vaylet C; Aparicio T; Rouzet F; Mignon M; Askienazy S; Sobhani I
    J Nucl Med; 2004 Oct; 45(10):1660-8. PubMed ID: 15471830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.
    Rufini V; Shulkin B
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):341-50. PubMed ID: 19088689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors.
    Sisson JC; Yanik GA
    Semin Nucl Med; 2012 May; 42(3):171-84. PubMed ID: 22475426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.